Importantly this enhanced immunogenicity has also been observed in vivo, where treatment of patients with BRAFi monotherapy or combined BRAF/MEK inhibition is associated with a more favorable tumor microenvironment within 10-14 d of initiation of therapy with enhanced melanoma antigen expression, increased CD8+ T-cell infiltrate, increased T-cell activation markers, and a decrease in the levels of immunosuppressive cytokines and the angiogenic factor VEGF.5,7,8. The gene discussed is BRAF; the disease is neoplasm.